Yesterday in the media and theNew England Journal of Medicineanarticlewas released. This meta-analysis implicated aPPAR gammaactivator named Rosiglitazone in the increased risk of heart attack, and death from heart attack. The risk fo heart attack was increased by 43% and the risk for death from cardiovascular causes was increased by 64%. Now before you get too crazy let's do some data analysis.
The study is a meta analysis of 42 articles. This methodology is fraught withproblems.
The second result....64% increased risk of death is not even statistically significant P value of 0.06 with a confidence interval which includes REDUCED RISK OF DEATH.
This study is a policy play, based on the fears of Vioxx.
The Gene Sherpa Says: Don't get me wrong, if you have risk of heart disease in the family, then you should not take this drug now. At least until a full proper study can be done. But please, don't freak out. Just talk to your doctor about this risk!
Yesterday in the media and theNew England Journal of Medicineanarticlewas released. This meta-analysis implicated aPPAR gammaactivator named Rosiglitazone in the increased risk of heart attack, and death from heart attack. The risk fo heart attack was increased by 43% and the risk for death from cardiovascular causes was increased by 64%. Now before you get too crazy let's do some data analysis.
The Gene Sherpa Says: Don't get me wrong, if you have risk of heart disease in the family, then you should not take this drug now. At least until a full proper study can be done. But please, don't freak out. Just talk to your doctor about this risk!